CDTX - a competitor to CYDY's CCR5 MOA? Abstra
Post# of 145339
![](/assets/46931549/no_avatar_available_thumb.jpg)
Abstract Title: CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
Presenter: Simon Döhrmann, Ph.D.
Session Category: Immunology
Session Title: Single Target and Bispecific Antibodies
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Poster Board Number: 22, Section 6
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)